SynthesisFrontiers in immunology2026
Effect of histology on the efficacy of first-line immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and network meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: First-line immune checkpoint inhibitors (ICIs) have become the standard of care for advanced non-small cell lung cancer (NSCLC). However, whether tumor histology influences the efficacy of ICIs remains unclear. Methods: We systematically searched PubMed, Embase, the Cochrane Library, Web of Science, and Scopus for randomized controlled trials (RCTs) published up to February 28, 2026. Eligible studies compared ICIs with chemotherapy, or two ICI-based regimens, as first-line treatment for advanced squamous (SQ) or non-squamous (non-SQ) NSCLC. Trials that enrolled patients with NSCLC and reported outcomes stratified by histology were also eligible. The primary outcome was overall survival (OS), reported as hazard ratios (HRs) with 95% credible intervals. A fixed-effects consistency model was used for the statistical analysis. Results: Forty-one phase 3 RCTs comprising 23, 871 patients and 31 ICI-based regimens were included. The efficacy of individual ICI regimens varied by histological subtype. For example, toripalimab plus chemotherapy was associated with superior OS compared with most other ICI regimens (HR range: 0.42-0.65) and ranked as the best treatment in non-SQ-NSCLC (surface under the cumulative ranking curve [SUCRA] = 0.97). In contrast, the same regimen showed inferior OS relative to many comparators (HR range for comparators vs. toripalimab plus chemotherapy: 0.47-0.65) and had the lowest OS ranking in SQ-NSCLC (SUCRA = 0.09). In the PD-L1 < 1% subgroup, nivolumab plus ipilimumab demonstrated a trend toward better OS compared with pembrolizumab plus chemotherapy (HR = 0.59) and ranked as the best regimen for SQ-NSCLC (SUCRA = 0.83), whereas pembrolizumab plus chemotherapy provided the greatest OS benefit for non-SQ-NSCLC (SUCRA = 0.90). In the PD-L1 ≥ 50% subgroup, atezolizumab plus chemotherapy ranked second for OS benefit in SQ-NSCLC but was the least effective combination in non-SQ-NSCLC; conversely, cemiplimab plus chemotherapy was the least effective combination in SQ-NSCLC but ranked second in non-SQ-NSCLC. Conclusions: The efficacy of individual first-line ICI regimens appear to vary by histological subtype across PD-L1 expression levels. These findings suggest that PD-L1 status alone might not be sufficient to guide treatment selection, and that histological subtype could be considered in clinical decision-making for advanced NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.